Effect of powder processing on performance of fenofibrate formulations

In this study, the effect of the order in which powder blending and jet-milling were performed for the production of the bulk powders on the performance of 200-mg dose orally disintegrating tablets (ODTs) of fenofibrate was evaluated. Bulk powders composed of fenofibrate, mannitol, copovidone S630,...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of pharmaceutics and biopharmaceutics Vol. 69; no. 2; pp. 727 - 734
Main Authors Jain, Rajeev A., Brito, Luis, Straub, Julie A., Tessier, Todd, Bernstein, Howard
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 01.06.2008
Elsevier Science
Subjects
Biological and medical sciences
Calorimetry, Differential Scanning
Chemistry, Pharmaceutical
Drug Compounding - instrumentation
Fenofibrate
Fenofibrate - administration & dosage
Fenofibrate - chemistry
General pharmacology
Hypolipidemic Agents - administration & dosage
Hypolipidemic Agents - chemistry
Jet-milling
Kinetics
Medical sciences
Microscopy, Electron, Scanning
ODTs
Particle Size
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Poorly soluble
Powders
Solubility
Tablets
ODTs
Fenofibrate
Poorly soluble
Jet-milling
Performance evaluation
Pharmaceutical technology
Fibrate derivatives
Formulation
Performance
Powder
Antilipemic agent
Online AccessGet full text

Cover

Abstract In this study, the effect of the order in which powder blending and jet-milling were performed for the production of the bulk powders on the performance of 200-mg dose orally disintegrating tablets (ODTs) of fenofibrate was evaluated. Bulk powders composed of fenofibrate, mannitol, copovidone S630, and docusate sodium in a 10:10:2:1.2 ratio were prepared by the following three processes: process A: fenofibrate + excipients → blending; process B: fenofibrate → jet-milling → blending with excipients; process C: fenofibrate + excipients → blending → jet-milling. The bulk powders were granulated followed by blending and tableting. The materials were tested for Differential Scanning Calorimetry (DSC), drug particle sizing post-reconstitution, dissolution, optical micrography, Scanning Electron Microscopy (SEM), Energy Dispersive X-ray Spectroscopy (EDS) and disintegration of the ODTs. It was found that the crystallinity of fenofibrate was not impacted by the blending and jet-milling processes. Process A produced materials having poorer fenofibrate reconstitution as compared to processes involving jet-milling. It was discovered that milling a blend of fenofibrate/excipient (process C) was advantageous over milling the raw drug alone (process B). Process C yielded bulk powder that showed rapid dissolution and ODTs which exhibited rapid disintegration.
AbstractList In this study, the effect of the order in which powder blending and jet-milling were performed for the production of the bulk powders on the performance of 200-mg dose orally disintegrating tablets (ODTs) of fenofibrate was evaluated. Bulk powders composed of fenofibrate, mannitol, copovidone S630, and docusate sodium in a 10:10:2:1.2 ratio were prepared by the following three processes: process A: fenofibrate+excipients-->blending; process B: fenofibrate-->jet-milling-->blending with excipients; process C: fenofibrate+excipients-->blending-->jet-milling. The bulk powders were granulated followed by blending and tableting. The materials were tested for Differential Scanning Calorimetry (DSC), drug particle sizing post-reconstitution, dissolution, optical micrography, Scanning Electron Microscopy (SEM), Energy Dispersive X-ray Spectroscopy (EDS) and disintegration of the ODTs. It was found that the crystallinity of fenofibrate was not impacted by the blending and jet-milling processes. Process A produced materials having poorer fenofibrate reconstitution as compared to processes involving jet-milling. It was discovered that milling a blend of fenofibrate/excipient (process C) was advantageous over milling the raw drug alone (process B). Process C yielded bulk powder that showed rapid dissolution and ODTs which exhibited rapid disintegration.
In this study, the effect of the order in which powder blending and jet-milling were performed for the production of the bulk powders on the performance of 200-mg dose orally disintegrating tablets (ODTs) of fenofibrate was evaluated. Bulk powders composed of fenofibrate, mannitol, copovidone S630, and docusate sodium in a 10:10:2:1.2 ratio were prepared by the following three processes: process A: fenofibrate+excipients-->blending; process B: fenofibrate-->jet-milling-->blending with excipients; process C: fenofibrate+excipients-->blending-->jet-milling. The bulk powders were granulated followed by blending and tableting. The materials were tested for Differential Scanning Calorimetry (DSC), drug particle sizing post-reconstitution, dissolution, optical micrography, Scanning Electron Microscopy (SEM), Energy Dispersive X-ray Spectroscopy (EDS) and disintegration of the ODTs. It was found that the crystallinity of fenofibrate was not impacted by the blending and jet-milling processes. Process A produced materials having poorer fenofibrate reconstitution as compared to processes involving jet-milling. It was discovered that milling a blend of fenofibrate/excipient (process C) was advantageous over milling the raw drug alone (process B). Process C yielded bulk powder that showed rapid dissolution and ODTs which exhibited rapid disintegration.
In this study, the effect of the order in which powder blending and jet-milling were performed for the production of the bulk powders on the performance of 200-mg dose orally disintegrating tablets (ODTs) of fenofibrate was evaluated. Bulk powders composed of fenofibrate, mannitol, copovidone S630, and docusate sodium in a 10:10:2:1.2 ratio were prepared by the following three processes: process A: fenofibrate + excipients → blending; process B: fenofibrate → jet-milling → blending with excipients; process C: fenofibrate + excipients → blending → jet-milling. The bulk powders were granulated followed by blending and tableting. The materials were tested for Differential Scanning Calorimetry (DSC), drug particle sizing post-reconstitution, dissolution, optical micrography, Scanning Electron Microscopy (SEM), Energy Dispersive X-ray Spectroscopy (EDS) and disintegration of the ODTs. It was found that the crystallinity of fenofibrate was not impacted by the blending and jet-milling processes. Process A produced materials having poorer fenofibrate reconstitution as compared to processes involving jet-milling. It was discovered that milling a blend of fenofibrate/excipient (process C) was advantageous over milling the raw drug alone (process B). Process C yielded bulk powder that showed rapid dissolution and ODTs which exhibited rapid disintegration.
Author Tessier, Todd
Bernstein, Howard
Jain, Rajeev A.
Straub, Julie A.
Brito, Luis
Author_xml – sequence: 1
  givenname: Rajeev A.
  surname: Jain
  fullname: Jain, Rajeev A.
  email: jain@acusphere.com
– sequence: 2
  givenname: Luis
  surname: Brito
  fullname: Brito, Luis
– sequence: 3
  givenname: Julie A.
  surname: Straub
  fullname: Straub, Julie A.
– sequence: 4
  givenname: Todd
  surname: Tessier
  fullname: Tessier, Todd
– sequence: 5
  givenname: Howard
  surname: Bernstein
  fullname: Bernstein, Howard
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20384005$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/18226885$$D View this record in MEDLINE/PubMed
BookMark eNp9kE1r3DAQhkVJaDYff6CH4ktyszsjy5YWcilh0xYCvbRnoZVGRYvXciVvSv59ZHZJbzkNDM87vPNcsrMxjsTYJ4QGAfsvu4Z207bhALJB3gD0H9gKlWzrVgg8YytYt-u6F4gX7DLnHQAI2amP7AIV571S3Yo9brwnO1fRV1P85yhVU4qWcg7jnyqO1UTJx7Q3o6WF8TRGH7bJzFQt-8Ng5hDHfM3OvRky3ZzmFfv9uPn18L1--vntx8PXp9q2Ssy19YCul-SsXDuJrfGdkMKBVOg611nhuFDC9Nw7QoEEZmuVELy3YG0p3F6xu-Pd0vLvgfKs9yFbGgYzUjxkLUF22K6hgPwI2hRzTuT1lMLepBeNoBd7eqcXe3qxp5HrYq-EPp-uH7Z7cv8jJ10FuD0BJlsz-FS8hPzGcShfAizc_ZGj4uI5UNLZBioOXUjFtnYxvNfjFfV_j6g
CitedBy_id crossref_primary_10_1007_s11095_010_0175_x
crossref_primary_10_1002_jps_23589
crossref_primary_10_1186_s11671_015_1085_y
crossref_primary_10_1016_j_addr_2015_12_022
crossref_primary_10_3390_pharmaceutics5010001
crossref_primary_10_1016_j_jpba_2013_02_036
crossref_primary_10_1016_j_ijpharm_2014_10_025
crossref_primary_10_1517_17425247_2010_511173
crossref_primary_10_1016_j_jddst_2020_101760
crossref_primary_10_1016_j_ejpb_2011_03_003
crossref_primary_10_1016_j_ejpb_2015_05_028
crossref_primary_10_1016_j_mseb_2021_115359
crossref_primary_10_3109_03639041003642081
crossref_primary_10_1208_s12249_010_9423_y
crossref_primary_10_1016_j_ajps_2014_12_006
Cites_doi 10.1081/PDT-120027417
10.1016/0378-5173(94)00132-4
10.1111/j.2042-7158.1976.tb02817.x
10.3109/03639049809082719
10.1016/S0378-5173(99)00347-6
10.1016/j.jconrel.2004.03.026
10.1016/0378-5173(94)90094-9
10.1016/S0378-5173(98)00247-6
10.1016/S0378-5173(99)00063-0
10.1016/0731-7085(95)01274-O
10.1016/j.jconrel.2005.02.010
10.1081/DDC-120030422
10.1023/A:1016232230638
10.1016/S0142-9612(00)00115-0
10.1016/0378-5173(94)90219-4
ContentType Journal Article
Copyright 2007 Elsevier B.V.
2008 INIST-CNRS
Copyright_xml – notice: 2007 Elsevier B.V.
– notice: 2008 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.ejpb.2007.12.006
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-3441
EndPage 734
ExternalDocumentID 10_1016_j_ejpb_2007_12_006
18226885
20384005
S0939641107004092
Genre Journal Article
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
29G
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATCM
AAXUO
AAYOK
ABFNM
ABFRF
ABGSF
ABJNI
ABMAC
ABUDA
ABXDB
ABYKQ
ABZDS
ACDAQ
ACGFO
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGRDE
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
C45
CS3
DOVZS
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HZ~
IHE
J1W
KOM
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SDF
SDG
SES
SEW
SPCBC
SSP
SSU
SSZ
T5K
TEORI
UNMZH
~G-
ABPIF
ABPTK
IQODW
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAXKI
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c384t-cf01d67edc79d713af5474d0781d5d5c4d2484a62fde141e0abc84426c0cc6883
IEDL.DBID .~1
ISSN 0939-6411
IngestDate Sat Aug 17 01:16:17 EDT 2024
Thu Sep 12 18:01:26 EDT 2024
Thu May 23 23:15:34 EDT 2024
Sun Oct 22 16:09:32 EDT 2023
Fri Feb 23 02:28:03 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords ODTs
Fenofibrate
Poorly soluble
Jet-milling
Performance evaluation
Pharmaceutical technology
Fibrate derivatives
Formulation
Performance
Powder
Antilipemic agent
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c384t-cf01d67edc79d713af5474d0781d5d5c4d2484a62fde141e0abc84426c0cc6883
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 18226885
PQID 70751390
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_70751390
crossref_primary_10_1016_j_ejpb_2007_12_006
pubmed_primary_18226885
pascalfrancis_primary_20384005
elsevier_sciencedirect_doi_10_1016_j_ejpb_2007_12_006
PublicationCentury 2000
PublicationDate 2008-06-01
PublicationDateYYYYMMDD 2008-06-01
PublicationDate_xml – month: 06
  year: 2008
  text: 2008-06-01
  day: 01
PublicationDecade 2000
PublicationPlace Amsterdam
PublicationPlace_xml – name: Amsterdam
– name: Netherlands
PublicationTitle European journal of pharmaceutics and biopharmaceutics
PublicationTitleAlternate Eur J Pharm Biopharm
PublicationYear 2008
Publisher Elsevier B.V
Elsevier Science
Publisher_xml – name: Elsevier B.V
– name: Elsevier Science
References Jain (bib8) 2000; 21
Ticehurst, Basford, Dallman, Lukas, Marshall, Nichols, Smith (bib26) 2000; 193
A. Stamm, P. Seth, Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it, US Patent 7,037,529 (2006).
A. Stamm, P. Seth, Fenofibrate pharmaceutical composition having high bioavailability, US Patent 7,041,319 (2006).
Sheu, Yeh, Sokoloski (bib14) 1994; 103
Florence, Salole (bib28) 1976; 28
Martin, Swarbrick, Cammarata (bib35) 1991
Munoz, Guichard, Reginault (bib16) 1994; 110
Rios (bib6) 2004; 28
A. Stamm, P. Seth, Fenofibrate pharmaceutical composition having high bioavailability, US Patent 6,652,881 (2003).
Ward, Shultz (bib27) 1995; 12
Führer (bib34) 1996
Kerč, Srčič, Knez, Senčar-Božič (bib15) 1999; 182
Hu, Johnston, Williams (bib3) 2004; 30
A.D. Edgar, F.C.O. Bellamy, Combination of fenofibrate and vitamin E, and method of use of same in therapeutic treatments, US Patent 5,880,148 (1999).
M. Hite, S. Turner, C. Federici, Part 1: Oral delivery of poorly soluble drugs, Pharm. Manuf. and Packing Sourcer, Autumn, 2003, pp. 38–40.
Cremer (bib10) 2001
Elamin, Ahlneck, Alderborn, Nyström (bib29) 1994; 111
Parrott (bib9) 1987
Pfister, Ghosh (bib11) 2005; 29
De Villiers, Tiedt (bib33) 1996; 51
J.E. Kipp, J.C.T. Wong, M.J. Doty, C.L. Rebbeck, Microprecipitation methods for preparing submicron suspensions, US Patent 7,037,528 (2001).
Jain, Shah, Malick, Rhodes (bib7) 1998; 24
T. Ryde, E.E. Gustow, S.B. Ruddy, R. Jain, R. Patel, M.J. Wilkins, Nanoparticulate fibrate formulations, US Patent 7,276,249 (2007).
De Villiers (bib32) 1995; 13
York, Ticehurst, Osborn, Roberts, Rowe (bib25) 1998; 174
Sant, Smith, Leroux (bib12) 2004; 97
C. Laruelle, Pharmaceutical dosage formulations of fenofibrate and their applications, US Patent 5,827,536 (1998).
Kharb, Bhatia, Dureja, Kaushik (bib4) 2006; 30
L. End, D. Horn, E. Lueddecke, Production of fine particle dye or drug preparations, US Patent 5,700,471 (1997).
Lipinski (bib1) 2002; 5
Sant, Smith, Leroux (bib13) 2005; 104
J.-R. Authelin, P. Hosek, Crystalline triamcinolone acetonide produced by a milling process, EU Patent EP1338273 (2003).
Rasenack, Muller (bib5) 2004; 9
Saleki-Gerhardt, Ahlneck, Zografi (bib24) 1994; 101
Elamin (10.1016/j.ejpb.2007.12.006_bib29) 1994; 111
Pfister (10.1016/j.ejpb.2007.12.006_bib11) 2005; 29
Florence (10.1016/j.ejpb.2007.12.006_bib28) 1976; 28
Sheu (10.1016/j.ejpb.2007.12.006_bib14) 1994; 103
Kerč (10.1016/j.ejpb.2007.12.006_bib15) 1999; 182
De Villiers (10.1016/j.ejpb.2007.12.006_bib32) 1995; 13
Rios (10.1016/j.ejpb.2007.12.006_bib6) 2004; 28
Parrott (10.1016/j.ejpb.2007.12.006_bib9) 1987
10.1016/j.ejpb.2007.12.006_bib17
10.1016/j.ejpb.2007.12.006_bib19
Kharb (10.1016/j.ejpb.2007.12.006_bib4) 2006; 30
10.1016/j.ejpb.2007.12.006_bib18
10.1016/j.ejpb.2007.12.006_bib2
Cremer (10.1016/j.ejpb.2007.12.006_bib10) 2001
Sant (10.1016/j.ejpb.2007.12.006_bib13) 2005; 104
10.1016/j.ejpb.2007.12.006_bib31
Sant (10.1016/j.ejpb.2007.12.006_bib12) 2004; 97
10.1016/j.ejpb.2007.12.006_bib30
Lipinski (10.1016/j.ejpb.2007.12.006_bib1) 2002; 5
Saleki-Gerhardt (10.1016/j.ejpb.2007.12.006_bib24) 1994; 101
York (10.1016/j.ejpb.2007.12.006_bib25) 1998; 174
Munoz (10.1016/j.ejpb.2007.12.006_bib16) 1994; 110
Jain (10.1016/j.ejpb.2007.12.006_bib7) 1998; 24
Hu (10.1016/j.ejpb.2007.12.006_bib3) 2004; 30
Führer (10.1016/j.ejpb.2007.12.006_bib34) 1996
Ticehurst (10.1016/j.ejpb.2007.12.006_bib26) 2000; 193
Ward (10.1016/j.ejpb.2007.12.006_bib27) 1995; 12
De Villiers (10.1016/j.ejpb.2007.12.006_bib33) 1996; 51
10.1016/j.ejpb.2007.12.006_bib23
10.1016/j.ejpb.2007.12.006_bib20
10.1016/j.ejpb.2007.12.006_bib22
10.1016/j.ejpb.2007.12.006_bib21
Martin (10.1016/j.ejpb.2007.12.006_bib35) 1991
Jain (10.1016/j.ejpb.2007.12.006_bib8) 2000; 21
Rasenack (10.1016/j.ejpb.2007.12.006_bib5) 2004; 9
References_xml – year: 2001
  ident: bib10
  article-title: Orally Disintegrating Dosage Forms
  contributor:
    fullname: Cremer
– volume: 13
  start-page: 191
  year: 1995
  end-page: 198
  ident: bib32
  article-title: Influence of cohesive properties of micronized drug powders on particle size analysis
  publication-title: J. Pharm. Biomed. Anal.
  contributor:
    fullname: De Villiers
– volume: 9
  start-page: 1
  year: 2004
  end-page: 13
  ident: bib5
  article-title: Micron-size drug particles: common and novel micronization techniques
  publication-title: Pharm. Dev. Technol.
  contributor:
    fullname: Muller
– volume: 28
  start-page: 40
  year: 2004
  end-page: 53
  ident: bib6
  article-title: Bringing formulations to size: strategies for micro- and nanoparticle development
  publication-title: Pharm. Tech.
  contributor:
    fullname: Rios
– volume: 21
  start-page: 2475
  year: 2000
  end-page: 2490
  ident: bib8
  article-title: The different techniques of manufacturing various biodegradable poly (lactide-
  publication-title: Biomaterials
  contributor:
    fullname: Jain
– volume: 12
  start-page: 773
  year: 1995
  end-page: 779
  ident: bib27
  article-title: Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability
  publication-title: Pharm. Res.
  contributor:
    fullname: Shultz
– volume: 103
  start-page: 137
  year: 1994
  end-page: 146
  ident: bib14
  article-title: Characterization and dissolution of fenofibrate solid dispersion systems
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Sokoloski
– volume: 111
  start-page: 159
  year: 1994
  end-page: 170
  ident: bib29
  article-title: Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Nyström
– volume: 28
  start-page: 637
  year: 1976
  end-page: 642
  ident: bib28
  article-title: Changes in crystallinity and solubility on comminution of digoxin and observations on spironolactone and estradiol
  publication-title: J. Pharm. Pharmacol.
  contributor:
    fullname: Salole
– start-page: 1
  year: 1996
  end-page: 15
  ident: bib34
  article-title: Interparticulate attraction mechanisms
  publication-title: Pharmaceutical Powder Compaction Technology
  contributor:
    fullname: Führer
– volume: 193
  start-page: 247
  year: 2000
  end-page: 259
  ident: bib26
  article-title: Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Smith
– volume: 51
  start-page: 564
  year: 1996
  end-page: 567
  ident: bib33
  article-title: An analysis of fine grinding and aggregation of poorly soluble drug powders in a vibrating ball mill
  publication-title: Pharmazie
  contributor:
    fullname: Tiedt
– start-page: 21
  year: 1987
  end-page: 46
  ident: bib9
  article-title: Milling
  publication-title: The Theory and Practice of Industrial Pharmacy
  contributor:
    fullname: Parrott
– volume: 29
  start-page: 136
  year: 2005
  end-page: 150
  ident: bib11
  article-title: Orally disintegrating tablets
  publication-title: Pharm. Tech.
  contributor:
    fullname: Ghosh
– volume: 30
  start-page: 233
  year: 2004
  end-page: 245
  ident: bib3
  article-title: Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs
  publication-title: Drug. Dev. Indust. Pharm.
  contributor:
    fullname: Williams
– volume: 97
  start-page: 301
  year: 2004
  end-page: 312
  ident: bib12
  article-title: Novel pH-sensitive supramolecular assemblies for oral delivery of poorly water soluble drugs: preparation and characterization
  publication-title: J. Control. Release
  contributor:
    fullname: Leroux
– volume: 24
  start-page: 703
  year: 1998
  end-page: 727
  ident: bib7
  article-title: Controlled drug delivery by biodegradable devices: different preparative approaches
  publication-title: Drug Dev. Indust. Pharm.
  contributor:
    fullname: Rhodes
– volume: 182
  start-page: 33
  year: 1999
  end-page: 39
  ident: bib15
  article-title: Micronization of drugs using supercritical carbon dioxide
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Senčar-Božič
– volume: 104
  start-page: 289
  year: 2005
  end-page: 300
  ident: bib13
  article-title: Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-
  publication-title: J. Control. Release
  contributor:
    fullname: Leroux
– volume: 101
  start-page: 237
  year: 1994
  end-page: 247
  ident: bib24
  article-title: Assessment of disorder in crystalline solids
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Zografi
– volume: 30
  start-page: 82
  year: 2006
  end-page: 92
  ident: bib4
  article-title: Nanoparticle technology for the delivery of poorly water-soluble drugs
  publication-title: Pharm. Tech.
  contributor:
    fullname: Kaushik
– volume: 174
  start-page: 179
  year: 1998
  end-page: 186
  ident: bib25
  article-title: Characterization of the surface energetics of milled dl-propanolol hydrochloride using inverse gas chromatography and molecular modeling
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Rowe
– start-page: 41
  year: 1991
  end-page: 61
  ident: bib35
  article-title: Atomic and molecular structure
  publication-title: Physical Pharmacy
  contributor:
    fullname: Cammarata
– volume: 5
  start-page: 82
  year: 2002
  end-page: 85
  ident: bib1
  article-title: Poor aqueous solubility – an industry wide problem in drug discovery
  publication-title: Am. Pharm. Rev.
  contributor:
    fullname: Lipinski
– volume: 110
  year: 1994
  ident: bib16
  article-title: Micronised fenofibrate
  publication-title: Atherosclerosis
  contributor:
    fullname: Reginault
– ident: 10.1016/j.ejpb.2007.12.006_bib22
– start-page: 21
  year: 1987
  ident: 10.1016/j.ejpb.2007.12.006_bib9
  article-title: Milling
  contributor:
    fullname: Parrott
– volume: 9
  start-page: 1
  issue: 1
  year: 2004
  ident: 10.1016/j.ejpb.2007.12.006_bib5
  article-title: Micron-size drug particles: common and novel micronization techniques
  publication-title: Pharm. Dev. Technol.
  doi: 10.1081/PDT-120027417
  contributor:
    fullname: Rasenack
– ident: 10.1016/j.ejpb.2007.12.006_bib18
– volume: 111
  start-page: 159
  year: 1994
  ident: 10.1016/j.ejpb.2007.12.006_bib29
  article-title: Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure
  publication-title: Int. J. Pharm.
  doi: 10.1016/0378-5173(94)00132-4
  contributor:
    fullname: Elamin
– volume: 51
  start-page: 564
  year: 1996
  ident: 10.1016/j.ejpb.2007.12.006_bib33
  article-title: An analysis of fine grinding and aggregation of poorly soluble drug powders in a vibrating ball mill
  publication-title: Pharmazie
  contributor:
    fullname: De Villiers
– volume: 28
  start-page: 637
  year: 1976
  ident: 10.1016/j.ejpb.2007.12.006_bib28
  article-title: Changes in crystallinity and solubility on comminution of digoxin and observations on spironolactone and estradiol
  publication-title: J. Pharm. Pharmacol.
  doi: 10.1111/j.2042-7158.1976.tb02817.x
  contributor:
    fullname: Florence
– volume: 24
  start-page: 703
  issue: 8
  year: 1998
  ident: 10.1016/j.ejpb.2007.12.006_bib7
  article-title: Controlled drug delivery by biodegradable devices: different preparative approaches
  publication-title: Drug Dev. Indust. Pharm.
  doi: 10.3109/03639049809082719
  contributor:
    fullname: Jain
– ident: 10.1016/j.ejpb.2007.12.006_bib20
– volume: 193
  start-page: 247
  year: 2000
  ident: 10.1016/j.ejpb.2007.12.006_bib26
  article-title: Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide
  publication-title: Int. J. Pharm.
  doi: 10.1016/S0378-5173(99)00347-6
  contributor:
    fullname: Ticehurst
– volume: 97
  start-page: 301
  issue: 2
  year: 2004
  ident: 10.1016/j.ejpb.2007.12.006_bib12
  article-title: Novel pH-sensitive supramolecular assemblies for oral delivery of poorly water soluble drugs: preparation and characterization
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2004.03.026
  contributor:
    fullname: Sant
– volume: 29
  start-page: 136
  year: 2005
  ident: 10.1016/j.ejpb.2007.12.006_bib11
  article-title: Orally disintegrating tablets
  publication-title: Pharm. Tech.
  contributor:
    fullname: Pfister
– volume: 103
  start-page: 137
  issue: 2
  year: 1994
  ident: 10.1016/j.ejpb.2007.12.006_bib14
  article-title: Characterization and dissolution of fenofibrate solid dispersion systems
  publication-title: Int. J. Pharm.
  doi: 10.1016/0378-5173(94)90094-9
  contributor:
    fullname: Sheu
– volume: 174
  start-page: 179
  year: 1998
  ident: 10.1016/j.ejpb.2007.12.006_bib25
  article-title: Characterization of the surface energetics of milled dl-propanolol hydrochloride using inverse gas chromatography and molecular modeling
  publication-title: Int. J. Pharm.
  doi: 10.1016/S0378-5173(98)00247-6
  contributor:
    fullname: York
– volume: 182
  start-page: 33
  issue: 1
  year: 1999
  ident: 10.1016/j.ejpb.2007.12.006_bib15
  article-title: Micronization of drugs using supercritical carbon dioxide
  publication-title: Int. J. Pharm.
  doi: 10.1016/S0378-5173(99)00063-0
  contributor:
    fullname: Kerč
– ident: 10.1016/j.ejpb.2007.12.006_bib31
– volume: 110
  issue: Suppl. 1
  year: 1994
  ident: 10.1016/j.ejpb.2007.12.006_bib16
  article-title: Micronised fenofibrate
  publication-title: Atherosclerosis
  contributor:
    fullname: Munoz
– volume: 28
  start-page: 40
  issue: 11
  year: 2004
  ident: 10.1016/j.ejpb.2007.12.006_bib6
  article-title: Bringing formulations to size: strategies for micro- and nanoparticle development
  publication-title: Pharm. Tech.
  contributor:
    fullname: Rios
– start-page: 1
  year: 1996
  ident: 10.1016/j.ejpb.2007.12.006_bib34
  article-title: Interparticulate attraction mechanisms
  contributor:
    fullname: Führer
– ident: 10.1016/j.ejpb.2007.12.006_bib21
– volume: 13
  start-page: 191
  year: 1995
  ident: 10.1016/j.ejpb.2007.12.006_bib32
  article-title: Influence of cohesive properties of micronized drug powders on particle size analysis
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/0731-7085(95)01274-O
  contributor:
    fullname: De Villiers
– ident: 10.1016/j.ejpb.2007.12.006_bib23
– volume: 30
  start-page: 82
  issue: 2
  year: 2006
  ident: 10.1016/j.ejpb.2007.12.006_bib4
  article-title: Nanoparticle technology for the delivery of poorly water-soluble drugs
  publication-title: Pharm. Tech.
  contributor:
    fullname: Kharb
– ident: 10.1016/j.ejpb.2007.12.006_bib2
– ident: 10.1016/j.ejpb.2007.12.006_bib19
– volume: 5
  start-page: 82
  year: 2002
  ident: 10.1016/j.ejpb.2007.12.006_bib1
  article-title: Poor aqueous solubility – an industry wide problem in drug discovery
  publication-title: Am. Pharm. Rev.
  contributor:
    fullname: Lipinski
– year: 2001
  ident: 10.1016/j.ejpb.2007.12.006_bib10
  contributor:
    fullname: Cremer
– volume: 104
  start-page: 289
  issue: 2
  year: 2005
  ident: 10.1016/j.ejpb.2007.12.006_bib13
  article-title: Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2005.02.010
  contributor:
    fullname: Sant
– volume: 30
  start-page: 233
  issue: 3
  year: 2004
  ident: 10.1016/j.ejpb.2007.12.006_bib3
  article-title: Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs
  publication-title: Drug. Dev. Indust. Pharm.
  doi: 10.1081/DDC-120030422
  contributor:
    fullname: Hu
– volume: 12
  start-page: 773
  year: 1995
  ident: 10.1016/j.ejpb.2007.12.006_bib27
  article-title: Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability
  publication-title: Pharm. Res.
  doi: 10.1023/A:1016232230638
  contributor:
    fullname: Ward
– volume: 21
  start-page: 2475
  year: 2000
  ident: 10.1016/j.ejpb.2007.12.006_bib8
  article-title: The different techniques of manufacturing various biodegradable poly (lactide-co-glycolide) (PLGA) devices
  publication-title: Biomaterials
  doi: 10.1016/S0142-9612(00)00115-0
  contributor:
    fullname: Jain
– volume: 101
  start-page: 237
  year: 1994
  ident: 10.1016/j.ejpb.2007.12.006_bib24
  article-title: Assessment of disorder in crystalline solids
  publication-title: Int. J. Pharm.
  doi: 10.1016/0378-5173(94)90219-4
  contributor:
    fullname: Saleki-Gerhardt
– start-page: 41
  year: 1991
  ident: 10.1016/j.ejpb.2007.12.006_bib35
  article-title: Atomic and molecular structure
  contributor:
    fullname: Martin
– ident: 10.1016/j.ejpb.2007.12.006_bib17
– ident: 10.1016/j.ejpb.2007.12.006_bib30
SSID ssj0004758
Score 2.0302694
Snippet In this study, the effect of the order in which powder blending and jet-milling were performed for the production of the bulk powders on the performance of...
SourceID proquest
crossref
pubmed
pascalfrancis
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 727
SubjectTerms Biological and medical sciences
Calorimetry, Differential Scanning
Chemistry, Pharmaceutical
Drug Compounding - instrumentation
Fenofibrate
Fenofibrate - administration & dosage
Fenofibrate - chemistry
General pharmacology
Hypolipidemic Agents - administration & dosage
Hypolipidemic Agents - chemistry
Jet-milling
Kinetics
Medical sciences
Microscopy, Electron, Scanning
ODTs
Particle Size
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Poorly soluble
Powders
Solubility
Tablets
Title Effect of powder processing on performance of fenofibrate formulations
URI https://dx.doi.org/10.1016/j.ejpb.2007.12.006
https://www.ncbi.nlm.nih.gov/pubmed/18226885
https://search.proquest.com/docview/70751390
Volume 69
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB5McimUkPQV5-HsIeTSqJbk0WOPJtQ4LZhAYvBt0b4gOUgidgi-5LdnVitFBNoeel1W0u7MaB67M98AnBdSSh2ZNEBp4gAp7gkkWh5wxaWSZJJ40WT5LtL5En-tktUArrpaGJdW2ep-r9Mbbd2OjFtqjuv7-_EtxeI8RRe_OEnkTg8jGSOS6R8vfZoHZk2PTjc5cLPbwhmf42UeaulhDN2RoOt69Gfj9LEu1kQy63td_N0ZbYzSbB_2Wm-STf2CD2Bgyk9wcePhqLeX7K6vrlpfsgt20wNVbz_DzEMXs8qyunrW5pHVvmyAzBmrSlb3RQVujjUlSaJ02BLMjbeNv9ZfYDn7eXc1D9q-CoGa5LgJlA0jnWZGq4xrClILm2CG2sH-6EQnCnWMORZpbLWJMDJhIVWOZMpVqFSa55OvsFNWpTkEJk2YcnoR53qCmqcyk5YiQqU4JkrbeAjfO4KK2sNniC6v7EE48rs-mJmIYkHkH0LS0Vy8EwJB-v2fz43eMejtU3FIGyY9M4SzjmOCfh93J1KUpnpai4xcJnKCwyF884zsl0muE202OfrPRR3DB59b4k5sTmBn8_hkTsmB2chRI6Ej2J1e_54vXgHWd_D1
link.rule.ids 315,786,790,4521,24144,27957,27958,45620,45714
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4heqBShVooZaHs-oC4QNgk6zx8rFBXW6AIiUXiZsUvCQ5JxC5CXPjtzMRJIyTg0GvkJPZ4Mg9n5vsA9gullIlsGnBl44Bj3hMo7kQgtFBaoUsSRVPle5HOrvnpTXKzAiddLwyVVba239v0xlq3V8atNMf17e34CnNxkXLKX0gTBdrhTxTOE3_D8XNf58GzhqSTRgc0vO2c8UVe9q5WHseQzgSJ9uht7_SlLhYoM-fJLt6PRhuvNP0K6204yX75GX-DFVtuwMGlx6N-OmLzvr1qccQO2GWPVP20CVOPXcwqx-rq0dh7Vvu-AfRnrCpZ3XcV0BhnS1RFReASjK63zF-L73A9_T0_mQUtsUKgJzlfBtqFkUkza3QmDGaphUt4xg3h_pjEJJqbmOe8SGNnbMQjGxZK5xx9uQ61TvN8sgWrZVXabWDKhqnABwlhJtyIVGXKYUqoteCJNi4ewGEnUFl7_AzZFZbdSRI_EWFmMoolin8ASSdz-UoLJBr4D-8bvtqgf6-KQ1wwGpoBjLodk_j90E-RorTVw0JmGDNhFBwO4IffyH6aGDvhYpOd_5zUCNZm87_n8vzPxdkufPaFJnR88xNWl_cPdg-jmaUaNtr6Aman8oc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+powder+processing+on+performance+of+fenofibrate+formulations&rft.jtitle=European+journal+of+pharmaceutics+and+biopharmaceutics&rft.au=Jain%2C+Rajeev+A&rft.au=Brito%2C+Luis&rft.au=Straub%2C+Julie+A&rft.au=Tessier%2C+Todd&rft.date=2008-06-01&rft.issn=0939-6411&rft.volume=69&rft.issue=2&rft.spage=727&rft.epage=734&rft_id=info:doi/10.1016%2Fj.ejpb.2007.12.006&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0939-6411&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0939-6411&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0939-6411&client=summon